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Abstract
Background: Sociodemographic, behavioral and clinical correlates of the vaginal microbiome (VMB) as characterized
by molecular methods have not been adequately studied. VMB dominated by bacteria other than lactobacilli may
cause inflammation, which may facilitate HIV acquisition and other adverse reproductive health outcomes.
Methods: We characterized the VMB of women in Kenya, Rwanda, South Africa and Tanzania (KRST) using a 16S rDNA
phylogenetic microarray. Cytokines were quantified in cervicovaginal lavages. Potential sociodemographic, behavioral,
and clinical correlates were also evaluated.
Results: Three hundred thirteen samples from 230 women were available for analysis. Five VMB clusters were
identified: one cluster each dominated by Lactobacillus crispatus (KRST-I) and L. iners (KRST-II), and three clusters not
dominated by a single species but containing multiple (facultative) anaerobes (KRST-III/IV/V). Women in clusters KRST-I
and II had lower mean concentrations of interleukin (IL)-1α (p < 0.001) and Granulocyte Colony Stimulating Factor
(G-CSF) (p = 0.01), but higher concentrations of interferon-γ-induced protein (IP-10) (p < 0.01) than women in clusters
KRST-III/IV/V. A lower proportion of women in cluster KRST-I tested positive for bacterial sexually transmitted infections
(STIs; ptrend = 0.07) and urinary tract infection (UTI; p = 0.06), and a higher proportion of women in clusters KRST-I and II
had vaginal candidiasis (ptrend = 0.09), but these associations did not reach statistical significance. Women who reported
unusual vaginal discharge were more likely to belong to clusters KRST-III/IV/V (p = 0.05).
Conclusion: Vaginal dysbiosis in African women was significantly associated with vaginal inflammation; the
associations with increased prevalence of STIs and UTI, and decreased prevalence of vaginal candidiasis, should be
confirmed in larger studies.
Keywords: Bacterial vaginosis, Vaginal microbiome, Vaginal microbiota, Lactobacillus, Candidiasis, Sexually transmitted
infections, Urinary tract infections, Women, HIV, Africa
Background
Lactobacilli-dominated vaginal microbiota (VMB) have
traditionally been considered to promote reproductive
health of women and their fetuses by maintaining a low
vaginal pH (<4.5), which restricts the growth of other
bacteria and yeasts [1]. The clinical conditions caused by an
imbalanced VMB include bacterial vaginosis (BV) and
bacterial vaginitis [2]. In addition, VMB-associated bacterial
communities may be influenced by other micro-organisms
in the vagina, such as Candida species, Trichomonas
vaginalis, and other sexually transmitted pathogens [3-6].
BV has traditionally been characterized as a reduction of
vaginal lactobacilli and an overgrowth of other (faculta-
tive) anaerobic bacteria. In clinical settings, BV is typically
diagnosed using Amsel criteria (three of the following 4
criteria should be present: 1) clue cells on wet mount
microscopy; 2) a ‘fishy’ odour after adding 10% KOH to
vaginal secretions; 3) vaginal pH > 4.5; and 4) thin,
homogenous vaginal discharge [2]. In 1991, Nugent and
colleagues developed a method that could be repeated by
scoring a Gram stained slide based on microscopic
visualization of three bacterial morphotypes (a Nugent
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score of 0–3 is considered normal vaginal microbiota, 4–6
intermediate microbiota, and 7–10 BV-positive) [7].
Nugent scoring is considered the gold standard for BV
diagnosis and is typically used in research settings.
Since 2002, an increasing number of VMB studies
have used molecular characterization of vaginal bacterial
communities, such as next generation sequencing, quan-
titative PCR or microarray analysis of bacterial 16S
rRNA genes. A recent review of 63 molecular VMB
studies conducted between 2008 and 2013 concluded
that lactobacilli-dominated VMB are indeed associated
with a healthy vaginal micro-environment (but that
Lactobacillus crispatus is more beneficial than L. iners)
and that BV is best described as a polybacterial dysbiosis
[6]. In most studies, the extent of dysbiosis correlated
well with Nugent score and vaginal pH but not with the
other Amsel criteria [3,6]. Some studies reported system-
atic VMB differences across ethnic groups, with Black
and Hispanic American women being less likely to have
a VMB dominated by L. crispatus, and having a higher
average vaginal pH, than White and Asian American
women [8-10]. However, data on VMB associations with
genital immune responses and other potential sociode-
mographic, behavioral and clinical correlates are scarce
and inconsistent [6].
The vaginal micro-environment is also important in
the context of vaginal product development, such as
vaginal microbicides for HIV prevention. Candidate
products should not disturb, and would ideally promote,
a lactobacilli-dominated VMB, and should not induce
vaginal inflammation [11,12]. In vaginal microbicide
safety trials, the VMB has traditionally been assessed by
Nugent scoring, and vaginal inflammation by visual
inspection during pelvic examination with or without
colposcopy and quantification of a select number of
cytokines in cervicovaginal lavages (CVLs) [12-15]. How-
ever, these data have always been difficult to interpret due
to insufficient understanding of the normal background
variation in women of different ages, behaviors and
clinical conditions.
Here, we describe the bacterial composition of the
VMB of different groups of women in four African
countries (Kenya, Rwanda, South Africa and Tanzania)
using traditional VMB characterization methods (Amsel
criteria and Nugent scoring) as well as molecular
methods (16S rDNA phylogenetic microarray). Potential
VMB correlates, including cytokine concentrations in
CVLs, and sociodemographic, behavioral, and clinical
characteristics were also evaluated.
Methods
Study design and ethical approvals
Samples for phylogenetic microarray testing as well as
data on potential VMB correlates were used from two
studies [16,17]. The study contributing most samples
and data was a multi-country prospective observational
cohort study aimed at characterizing novel safety bio-
markers for vaginal HIV microbicide development in
East and South Africa (referred to as the Vaginal Bio-
markers Study). The study was conducted in 2011–2012
with a cohort of 430 women from three African countries
(Kenya, Rwanda and South Africa; Additional file 1). The
participants included 109 HIV-negative adult women each
in Kenya and South Africa, 30 HIV-negative adolescent
women each in Kenya and South Africa, 30 HIV-negative
pregnant women each in Kenya and South Africa, 31
HIV-negative women using traditional vaginal practice in
South Africa, 30 HIV-negative adult women at high risk
for HIV (mostly female sex workers) in Rwanda, and 30
HIV-positive women in Rwanda.
The second study was an intensive longitudinal study
cohort of women conducted in 2009 for evaluating the
impact of traditional vaginal practices on the vaginal
micro-environment in Northwest Tanzania (referred to
as the Tanzania Study; Additional file 1). Study partici-
pants were 100 women working in bars, guest-houses
and other food and recreational facilities located in three
towns adjacent to large gold or diamond mines [17,18].
Both studies were approved by all relevant institutional
and national ethics committees (Additional file 1). All
participants (or their guardians in the case of minors)
provided written informed consent and received a modest
reimbursement for each study visit (Additional file 1).
Study procedures
In the Vaginal Biomarkers Study, women were screened,
and eligible consenting women were enrolled within four
days of the last day of their menstrual period (visit 1).
Most study groups described above included healthy,
non-pregnant, HIV-negative women between 16 and 35
years of age. The pregnant women group included women
who were at most 14 weeks into gestation as determined
by abdominal ultrasound, and the HIV-positive women
group consisted of women on antiretroviral treatment
(ART) for at least six months, currently asymptomatic
and with a CD4 count above 350 cells/μl. Women were
excluded from all groups if they had a history of hysterec-
tomy or other genital tract surgery in the three months
before the screening visit; never had had penetrative
vaginal intercourse; were enrolled in an HIV prevention
study involving investigational products; had internal and/
or external genital warts at screening and/or enrollment;
or were breastfeeding and less than six months post-
partum at the time of enrollment. Once enrolled, women
returned for six follow-up visits (visits 2 to 5 at biweekly
intervals over two menstrual cycles, and visits 6 and 7 at
three and six months after visit 5), but this paper focuses
on the screening and enrollment (visit 1) visits. The
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median time between these visits was 25 days (interquar-
tile range (IQR) 14 – 39 days). At screening, women
underwent face-to-face interviews, blood and urine sam-
ple collection with real-time HIV, pregnancy and urinary
tract infection (UTI) testing, a pelvic examination with
sample collection, and a general physical exam. Samples
were subsequently tested for several sexually transmitted
infections (STIs; see below), UTIs, BV by Amsel and
Nugent criteria, and vaginal candidiasis. At enrollment,
additional samples were collected for microarray testing
and immunological assessments (see below).
In the Tanzania Study, participants were enrolled at
any time during their menstrual cycle and followed every
two to three days for four weeks (12 visits in total). For
the microarray testing, two pairs of samples from 20
women (two to four weeks apart) were selected. At each
visit women underwent a face-to-face interview, physical
examination, pelvic examination, and sample collection
for STI and BV by Nugent scoring. Samples for micro-
array analysis were collected either at enrollment (8
women) or visit 6 (12 women).
Participants in both studies received counseling and
condoms free of charge. Women who tested positive for
curable STIs, UTI, or symptomatic BV or vaginal can-
didiasis were treated by study clinicians using national
treatment guidelines. All HIV-positive and pregnant
women were linked to appropriate care in local public
clinics.
Diagnostic and immunological testing
Cervicovaginal samples were collected in the following
order: vaginal pH measurement, vaginal samples, CVLs,
and endocervical specimens. All diagnostic tests were
conducted at the study sites in Africa, and similar tests
were used in the two studies, unless otherwise stated
(see Additional file 1 for diagnostic details). HIV status
was determined by locally approved rapid testing algo-
rithm. Plasma samples were tested for herpes simplex
type 2 (HSV-2) antibodies and for syphilis by Rapid
Plasma Reagin test with confirmation by a Treponema
pallidum-specific test. Endocervical swabs were tested
for Neisseria gonorrhoeae and Chlamydia trachomatis by
PCR. Vaginal swabs were used to prepare a wet mount
(detection of trichomonads and clue cells, and after
KOH addition yeasts and amine smell), a Gram stain for
Nugent scoring (done centrally at the Institute of Tropical
Medicine in Antwerp), and to inoculate Trichomonas
vaginalis cultures. UTIs were diagnosed by the presence
of white blood cells on a urine dipstick test and pregnancy
by urine hCG test. Vaginal pH was measured using pH
paper strips (pH range 3.6-6.1).
CVLs were obtained by irrigating the cervix and lateral
vaginal walls with 10 ml of sterile normal saline (5 ml of
saline in Tanzania), immediately stored at 4–8°C, and
processed within two hours of collection. They were
centrifuged for 10 minutes at 1,000 rpm (3,500 rpm in
Tanzania), and the resulting supernatant and pellet
were stored separately at −80°C until shipment. Soluble
markers of inflammation in CVLs were quantified by
Bio-Plex (Bio-Rad Laboratories NV-SA, Nazareth, Belgium)
or ELISA at the ITM in Antwerp in the Vaginal Biomarkers
Study [19], and by an in house multiplex bead immuno-
assay at St. Georges University in London in the Tanzania
Study as described previously [20,21].
Samples for microarray testing
Two sterile Copan vaginal swabs were collected per
participant per visit. Copan vaginal swabs were shipped
frozen to the ITM in Antwerp. Upon arrival, each swab
tip was thawed at room temperature for 30 minutes,
1200 μl of diluted PBS (1 PBS: 9 saline, pH 7.4) was
added, and the sample was vortexed for 15 seconds. An
aliquot of 600 μl was sent on dry ice to TNO (Zeist, the
Netherlands) for phylogenetic microarray analysis. We
could not test all available samples by microarray due to
funding constraints. In the Vaginal Biomarkers Study,
only the samples from 216 women that were available in
October 2011 were analyzed. These 216 women each
contributed one enrollment sample, 34 women also con-
tributed 61 follow-up samples, and two samples had
missing clinical data. Tanzania Study participants con-
tributed 20 enrollment and 20 follow-up samples. After
excluding six poor quality samples, the total sample size
was 313 samples from 232 women. All 313 samples were
used for phylogenetic clustering and ecological analyses,
but only one enrollment sample per woman with clinical
data (N = 230) was used for all other analyses.
Microarray testing
The phylogenetic microarray (V-Chip, TNO, Zeist, The
Netherlands) has been described previously [3,22]. Briefly,
it contained 283 DNA hybridization probes that gener-
ated a consistent signal with a signal/background (S/B)
ratio > 5, of which 74 16S probes were species-specific,
60 16S probes targeted multiple bacterial species within
one genus, 42 16S probes were specific at family or
order level, 85 targeted higher taxonomic levels, five
were groEL probes, 14 were 18S probes, and three were
viral probes. We focused our clustering analyses on
these 283 probes, and all additional analyses on the 134
16S probes generating species or genus-specific signals.
A probe targeting a bacterium classified by the Ribosomal
Database Project as an uncultured bacterium in the
Lachnospiraceae family matched perfectly with a bacter-
ium recently named BV-associated bacterium 1 (BVAB1)
in Genbank (Genbank entry AY724739.1) [23]. We refer
to it as BVAB1 and included it in the 134 species/genus-
specific probes.
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Microarray sample preparation and labeling, amplifica-
tion and hybridization were described elsewhere [9,22].
Imagene 5.6 software (BioDiscovery, Marina del Rey,
USA) was used to read the scanned results and quantify
the signal (S) and the background (B). Ratios for S and
B were calculated and if S was not confidently above B
(S > B + 2*standard deviation (SD) of B), the S/B ratio
was set to 1. Slide normalization was performed by
Lowess smoothing [24]. We used normalized S/B ratios to
estimate bacterial loads, referred to from here onwards as
‘abundance’.
Statistical analysis
Clustering analysis was performed using Python 2.7.2 ver-
sion (Python Software Foundation, https://www.python.
org/download/releases/2.7.2/). Other statistical analyses
were performed using R 3.0.2 version (R Development
Core Team, 2013), MATLAB (R2012a, The Math Works,
Natick, USA), STATA release 12 (StataCorp, TX, USA)
and MS Excel (Microsoft, Washington, USA).
Neighborhood co-regularized multi-view spectral clus-
tering of normalized S/B ratios was used to identify VMB
clusters as described before [3,25]. These clusters were
named KRST-I to KRST-V (with KRST denoting Kenya,
Rwanda, South Africa, and Tanzania). For each sample,
the probability of belonging to a particular cluster was
calculated by probability decomposition of the co-
occurrence matrix. A cut-off probability of 70% was used
to assign samples to a cluster. For each cluster, the follow-
ing microbial ecology parameters were computed: rich-
ness (median number of genera), evenness (expressed as a
community organization value (Co-value) with 0 repre-
senting complete evenness and 100 complete unevenness
[26], and the Shannon diversity index [27]. We focused
the evenness calculations on the five most abundant
bacteria in each cluster to reduce the influence of the long
tail of minority species [26]. To compare cumulative
Co-values per cluster, an average sample per cluster
was generated by calculating median S/B ratios per
genus across the samples in that cluster.
To assess associations between VMB clusters and poten-
tial correlates, we only included one sample per woman
with clinical data (N = 230) and excluded women who
could not be assigned to a cluster with at least 70%
probability (N = 22). To improve statistical power, the
three dysbiotic clusters (KRST-III, KRST-IV and KRST-V)
were pooled, and the pooled cluster is referred to as
KRST-pIII-V (p for pooled). In regression models, KRST-
II and KRST-pIII-V were each compared to KRST-I. VMB
correlates were grouped into three groups: 1) sociode-
mographics, sexual behavior and reproductive history;
2) self-reported symptoms, clinician-observed findings
and antibiotic use; and 3) cervicovaginal immunology.
Unadjusted associations were assessed by one way
ANOVA for continuous variables and Fisher’s exact test
for categorical variables; p values were adjusted for false
discovery using the linear step up Benjamini-Hochberg
procedure, assuming a false discovery rate q = 0.1 and a
significance level α = 0.1. An adjusted p value of 0.01
(α = 0.1 * q = 0.1) was considered statistically significant.
Adjusted associations were assessed by multinomial logis-
tic regression models with stepwise backward elimination
using p ≤ 0.2 as the cut-off in unadjusted models. The
final model was selected based on the smallest Akaike
Information Criteria (AIC). Microarray testing was done
in two batches but we found no evidence for a batch effect
in our analyses.
Results
VMB clusters
We identified five VMB clusters, which are visualized in
a co-occurrence matrix (Additional file 1: Figure S1A-C).
Thirty-five samples from 22 women had a probability
of <70% belonging to one of the five clusters (Additional
file 1: Figure S1A). These samples did not cluster together,
and the sociodemographic, behavioral and clinical charac-
teristics of the 22 women did not differ significantly from
those of the 208 women who were assigned to a cluster
(Additional file 1: Tables S1 and S2).
The VMB clusters were characterized using ecological
parameters (below), Co-values (Figure 1), and a heatmap
of S/B ratios of bacteria that were most abundant in this
study or have been reported as important in previous
studies [3] (Figure 2). Cluster KRST-I was dominated by
L. crispatus and did not contain other bacterial taxa in
high abundance. Only 19 women (9%) were assigned to
this cluster. Cluster KRST-II was dominated by L. iners,
but some samples also had high abundance of Gardnerella
vaginalis, Atopobium vaginae, and Prevotella spp (Figure 2).
Cluster KRST-II included the majority of women (n = 136,
65.4%). Clusters KRST-III, IV and V each contained mul-
tiple anaerobic species in high abundance (most notably G.
vaginalis, A. vaginae, and Prevotella spp.) but in different
proportions, and a lower abundance of lactobacilli than
clusters KRST-I and II. About a quarter (25.5%) of the
women were assigned to the combined cluster KRST-pIII-
V. Cluster KRST-III had the highest abundance of Dialis-
ter, Megasphaera spp. and Mobiluncus spp. and the lowest
abundance of L. iners. Cluster KRST-IV had the highest
abundance of Prevotella spp. and the lowest abundance of
BVAB1 and Megasphaera spp. Cluster KRST-V contained
a higher abundance of L. iners and other Lactobacillus spp.
than clusters KRST-III and IV.
The bacterial diversity increased from cluster KRST-I
(median Shannon index of 1.0) to cluster KRST-II (1.2) to
clusters KRST-III, IV and V (2.1, 2.0, and 2.0, respectively;
p <0.01). The evenness based on the five most abundant
genera in each cluster was lower in clusters KRST-I and
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Figure 1 Median abundance and evenness per cluster. (a) For each median sample per cluster, the cumulative co-values for the five most
abundant genera in descending order are plotted. In (b) the actual genera present in each cluster are shown; this clearly illustrates the dominance of
lactobacilli in clusters KRST-I and II, and a more even distribution of the other 18 most abundant anaerobic genera in other clusters. Cluster KRST-II also
contained Atopobium vaginae and Prevotella spp., but these are not visible in (b) because their abundance in most samples was low. They are visible in
the heatmap in Figure 2.
Figure 2 Bacterial composition of the cervicovaginal microbiome clusters. (a) shows the five clusters identified by Neighborhood Co-regularized
Multi-view Spectral Clustering of microarray data. The white space in between clusters represents samples with less than 70% probability of belonging
to a cluster. (b) Heatmap, showing normalized S/B ratios of 33 bacterial species/genera, including the most abundant species/genera per cluster and
those traditionally known to be associated with BV and frequently reported in literature. 1Abbreviated probe name: additional targeted species in the
same genus are provided in supplementary information of previously published work [3]. 2Abbreviated for Prevotella.
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Table 1 Sociodemographic, behavioral, and reproductive history correlates of VMB clusters
Correlates KRST-I n (%) N = 19 KRST-II n (%) N = 136 KRST-pIII-V n (%) N = 53 p value*
Sociodemographic characteristics at screening
Recruitment group:
Adult women, KE 9 (47.4) 60 (44.1) 21 (39.6) 0.69
Adolescent women, KE 1 (5.3) 14 (10.3) 4 (7.5)
Pregnant women, KE 3 (15.8) 9 (6.6) 2 (3.8)
Adult women, RSA 2 (10.5) 22 (16.2) 7 (13.2)
IVP users, RSA + TZ 2 (10.5) 10 (7.4) 8 (15.1)
HIV-positive and high risk women, RW 2 (10.5) 21 (15.4) 11 (20.8)
Country:
Kenya 13 (68.4) 83 (61.0) 27 (50.9) 0.69
RSA 2 (10.5) 22 (16.2) 8 (15.1)
Rwanda 2 (10.5) 21 (15.4) 11 (20.8)
Tanzania 2 (10.5) 10 (7.4) 7 (13.2)
Age (categorical):
16 -17 years 1 (5.3) 14 (10.3) 4 (7.5) 0.18
18 -24 years 3 (15.8) 50 (36.8) 20 (37.7)
25 -29 years 6 (31.6) 48 (35.3) 17 (32.1)
30 -35 years 9 (47.4) 24 (17.6) 12 (22.6)
Socio-economic status (composite)a:
Low 6 (31.6) 42 (30.9) 15 (28.3) 0.58
Medium 5 (26.3) 44 (32.4) 23 (43.4)
High 8 (42.1) 50 (36.8) 15 (28.3)
Sexual behavior
Sexual risk taking (composite)b:
Low 7 (36.8) 55 (40.4) 22 (41.5) 0.63
Medium 6 (31.6) 42 (30.9) 11 (20.8)
High 6 (31.6) 39 (28.7) 20 (37.7)
Self-acknowledged sex-worker:
No 16 (84.2) 115 (84.6) 43 (81.1) 0.88
Yes 3 (15.8) 21 (15.4) 10 (18.9)
Number of lifetime sexual partnersc:
One 7 (38.9) 29 (21.6) 10 (20.8) 0.55
Two to three 7 (38.9) 55 (41) 20 (41.7)
More than three 4 (22.2) 50 (37.3) 18 (37.5)
Number of sexual partners last 3 monthsd:
Zero 3 (15.8) 11 (8.2) 1 (1.9) 0.24
One 12 (63.2) 101 (75.4) 42 (79.2)
> One 4 (21.1) 22 (16.4) 10 (18.9)
Vaginal sex previous morning/eveninge:
No 18 (94.7) 97 (71.9) 40 (75.5) 0.09
Yes 1 (5.3) 38 (28.1) 13 (24.5)
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Table 1 Sociodemographic, behavioral, and reproductive history correlates of VMB clusters (Continued)
Frequency of sex last 3 monthsf:
≤10 times 7 (50.0) 45 (38.8) 20 (42.6) 0.21
11 - 30 times 6 (42.9) 36 (31.0) 19 (40.4)
>30 times 1 (7.1) 35 (30.2) 8 (17.0)
Condom use last sexual contactf:
No 13 (81.2) 70 (60.3) 32 (68.1) 0.24
Yes 3 (18.8) 46 (39.7) 15 (31.9)
Freq of unprotected sex (last 3 months)g:
Never 0 (0.0) 36 (60.0) 12 (63.2) 0.06
<10 times 2 (40.0) 13 (21.7) 4 (21.1)
≥10 times 3 (60.0) 11 (18.3) 3 (15.8)
Put something in vagina to dry/tighten vagina before sex (enrollment)h
No 17 (100.0) 125 (99.2) 46 (100.0) 1.00
Yes 0 (0.0) 1 (0.8) 0 (0.0) 1.00
Clean vagina after sex (enrollment):
No 7 (36.8) 67 (49.3) 28 (52.8) 0.50
Yes 12 (63.2) 69 (50.7) 25 (47.2)
Vaginal practice for washing:
No 7 (36.8) 51 (37.5) 21 (39.6) 0.88
Yes, but not the evening before visit 3 (15.8) 14 (10.3) 7 (13.2)
Yes, including evening before visit 9 (47.4) 71 (52.2) 25 (47.2)
Products used to wash/clean/dry vagina
No product 6 (31.6) 51 (37.5) 20 (37.7) 0.48
Water or fingers only 6 (31.6) 39 (28.7) 17 (32.1)
Water + soap 3 (15.8) 35 (25.7) 14 (26.4)
Cloth 4 (21.1) 11 (8.1) 2 (3.8)
Reproductive history at screening
Median gravidity (IQR) 2 (1, 3) 2 (1, 3) 2 (1, 3) 0.78
Median parity (IQR) 2 (1, 2.5) 1.5 (0, 2) 1 (0, 2) 0.76
Currently pregnant
No 16 (84.2) 127 (93.4) 51 (96.2) 0.19
Yes 3 (15.8) 9 (6.6) 2 (3.8)
Breast feeding:
No 16 (84.2) 119 (87.5) 49 (92.5) 0.48
Yes 3 (15.8) 17 (12.5) 4 (7.5)
Median months since last deliveryi† (IQR) 41 (28, 54) 33 (19, 48) 56 (28, 82) 0.01
Current contraceptive use:
None, pregnant 3 (15.8) 9 (6.6) 2 (3.8) 0.58
None, not pregnant 3 (15.8) 30 (22.1) 13 (24.5)
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KRST-II compared to cluster KRST-pIII-V (Figure 1a).
The richness in clusters KRST-I and KRST-II (a median of
four and five genera per sample) was lower than in clus-
ters KRST-III, IV and V (16, 14, and 14 genera per sample,
respectively) (Figure 1b).
Sociodemographic, behavioral and reproductive history
correlates of VMB clusters
VMB clustering was not associated with sociodemographic,
behavioral or reproductive history characteristics, with the
exception of time elapsed since last delivery (Table 1). With
every additional month since last delivery, women were
less likely to be assigned to cluster KRST-II than cluster
KRST-pIII-V (p = 0.01). We did not conduct multivariable
modeling with this group of variables because few of them
were significant at p ≤ 0.01 in bivariable models.
Associations between VMB clusters, Nugent scores and
Amsel criteria
Diagnosis of BV by Nugent score and Amsel criteria were
each strongly associated with VMB clustering (p < 0.0001)
(Table 2, Figure 3). The majority (>88%) of women in clus-
ters KRST-I and II were diagnosed as BV-negative by
Nugent score and Amsel criteria. However, while the
majority of women (89.6%) in cluster KRST-pIII-V was
diagnosed as BV-positive by Nugent score, only 30% were
diagnosed as BV-positive by Amsel criteria. Only 9.6% of
women were diagnosed with intermediate microbiota by
Nugent score and approximately equal proportions were
found in each VMB cluster (Figure 3).
Clinical correlates of VMB clusters
The proportions of women with laboratory-confirmed
bacterial STIs (5.6% in KRST-I, 14.7% in KRST-II and
22.6% in KRST-pIII-V), HSV-2 (21.1%, 37.5%, and 37.7%)
and HIV (0%, 5.2%, and 5.7%) increased from cluster
KRST-I to KRST-pIII-V, indicating a trend although
the evidence for an association was weak (ptrend = 0.07
for STIs, 0.34 for HSV2 and 0.44 for HIV) (Table 2,
Additional file 1: Figure S2). No women in cluster
KRST-I had an UTI compared to 55.6% in cluster
KRST-II and 23.7% in cluster KRST-pIII-V (p = 0.06;
Table 2). Women with abundant cervical mucus upon
speculum examination were more likely to belong to
cluster KRST-I, but the total number of women with
abundant cervical mucus was small (p = 0.04; Table 2).
Women who reported unusual vaginal discharge were
more likely to belong to cluster KRST-pIII-V (p = 0.05;
Table 2). There was no evidence for an association
between VMB clustering and any other clinical character-
istics. We did not conduct multivariable modeling with
this group of variables due to the fact that few of them
were significant at p ≤ 0.01 in bivariable models.
Immunological correlates of VMB clusters
The bivariable models showed strong evidence for an
increase of the pro-inflammatory cytokines and growth
factors IL-1α, IL-1β, G-CSF, and GM-CSF, and a decrease
of IP-10, when moving from cluster KRST-I to KRST-pIII-
V (Table 3). The MIP-1β concentration was highest in
cluster KRST-II and lowest in cluster KRST-I. Six variables
(IL-1α, IL-1β, G-CSF, GM-CSF, IP-10, and MIP-1β) quali-
fied for inclusion in the multivariable model, but the final
model (AIC = 296) included only four of them (IL-1α,
G-CSF, IP-10, and MIP-1β). IL-1β, which was highly
significant in the bivariable analysis, was eliminated due
to its high correlation with IL-1α (Pearson’s correlation
Table 1 Sociodemographic, behavioral, and reproductive history correlates of VMB clusters (Continued)
Combined oral contraceptives 3 (15.8) 19 (14.0) 9 (17.0)
Progestin-only injectables 5 (26.3) 44 (32.4) 11 (20.8)
Condoms + IUD 5 (26.3) 34 (25.0) 18 (34.0)
Abbreviations: IQR inter quartile range, IUD intra uterine device, IVP intravaginal practice, KE Kenya, KRST Kenya, Rwanda, South Africa and Tanzania, RSA Republic
of South Africa, RW Rwanda, TZ Tanzania.
*Kruskal-Wallis test for continuous data and Fisher’s exact test for categorical data.
aThe composite score ‘socio-economic-status’ was calculated as follows: income: no income (=1), up to the median (=2), median to 75th percentile (=3), and ≥ 75th
percentile (=4); housing: informal dwelling (=1), room inside house or flat (=2), rented house or flat (=3), bonded/mortgaged house or flat (=4); and toilet: no facility/
bush/field/yraditional pit toilet (=1), ventilated improved pit latrine (=2), and flush toilet (=3). The total score was categorized in tertiles as low, medium, high.
bThe composite variable for sexual risk taking was constructed as follows: High risk: sex worker OR at least three sex partners last year OR had at least one sex
partner (in the last 3 months) with HIV OR age first sex less than 15 yrs; Medium risk: at least two sex partners last year OR had at least one sex partner (in the last
3 months) who had multiple partners; Low risk: one or no sex partners in last year AND did not have any sex partner (in the last 3 months) with multiple partners
AND age first sex at least 15 years.
c8/208 values missing.
d2/208 values missing.
e1/208 values missing.
f30/208 values missing.
g124/208 values missing.
h19/208 values missing.
i71/208 values missing.
†For every one month increase in the time since last delivery, women were less likely to be assigned to cluster KRST-II than cluster KRST-pIII-V (OR = 0.98; 95% CI
0.97, 0.99). Time since last delivery was not statistically significantly different between clusters KRST-I and KRST-II, and between clusters KRST-I and KRST-pIII-V.
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Table 2 Clinical correlates of VMB clusters.
Correlates KRST-I n (%) N = 19 KRST-II n (%) N = 136 KRST-pIII-V n (%) N = 53 p value*
Self reported symptoms at screening
Vaginal discharge reported:
No 18 (8.9) 135 (66.5) 50 (24.6) 0.05
Yes 1 (20.0) 1 (20.0) 3 (60.0)
Clinician observed findings at screening
Cervical mucusab†:
No 5 (4.2) 82 (69.5) 31 (26.3) 0.04
Mild 11 (14.1) 48 (61.5) 19 (24.4)
Abundant 2 (28.6) 3 (42.9) 2 (28.6)
Cervical and/or vaginal epithelial abnormalities:
No 15 (8.0) 124 (66.3) 48 (25.7) 0.26
Yes 4 (19.0) 12 (57.1) 5 (23.8)
Ectopy:
No 11 (9.4) 73 (62.4) 33 (28.2) 0.57
Yes 8 (8.8) 63 (69.2) 20 (22)
Any colposcopy finding?:
No 17 (9.4) 119 (65.7) 45 (24.9) 0.90
Yes 2 (7.4) 17 (63.0) 8 (29.6)
Laboratory-confirmed reproductive and urinary tract infections
HIV serology
Negative 19 (100.0) 128 (94.8) 50 (94.3) 0.78
Positive 0 (0.0) 7 (5.2) 3 (5.7) Trend: 0.44
HSV-2 serology
Negative 15 (78.9) 85 (62.5) 33 (62.3) 0.36
Positive 4 (21.1) 51 (37.5) 20 (37.7) Trend: 034
Bacterial STIc
Negative 17 (94.4) 116 (83.3) 41 (77.4) 0.20
Positive 1 (5.6) 20 (14.7) 12 (22.6) Trend: 0.07
BV by Nugent score
0-3 15 (93.8) 93 (76.2) 2 (4.2) <0.01
4-6 1 (6.2) 15 (12.3) 3 (6.3)
7-10 0 (0.0) 14 (11.5) 43 (89.6)
BV by Amsel criteria
Negative 18 (94.7) 128 (94.1) 37 (69.8) <0.01
Positive 1 (5.3) 8 (5.9) 16 (30.2)
Candidiasis on wet mountd
Negative 16 (84.2) 113 (83.1) 50 (94.3) 0.11
Positive 3 (15.8) 23 (16.9) 3 (5.7) Trend: 0.09
Urinary tract infection by diptstick test
Negative 4 (100.0) 4 (44.4) 132 (76.3) 0.06
Positive 0 (0.0) 5 (55.6) 41 (23.7)
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coefficient = 0.65). The associations in the final model
were in the same direction as in the bivariable models.
Discussion
We identified five vaginal microbiota clusters in a diverse
group of women from four African countries. Two of
these clusters were dominated by L. crispatus or L. iners,
while the other three clusters consisted of various combi-
nations of other (facultative) anaerobic bacteria in addition
to L. iners. Studies in the USA, Europe and Asia have also
reported clusters dominated by L. crispatus and L. iners,
but L. crispatus clusters were typically more common
and L. iners clusters less common than in our study
[8,10,28,29]. Longitudinal studies have shown that L.
crispatus protects women from vaginal dysbiosis more
efficiently than L. iners (reviewed in 6). We did not
identify any clusters dominated by L. gasseri or L. jensenii.
Such clusters have been reported in studies in the USA,
Table 2 Clinical correlates of VMB clusters. (Continued)
Treatment in the 14 days prior to enrollment
Any systemic antibioticsd:
No 18 (10.5) 115 (66.9) 39 (22.7) 0.10
Yes 1 (2.8) 21 (58.3) 14 (38.9)
Any vaginal antibiotics: No
No 19 (9.2) 136 (66) 51 (24.8) 0.12
Yes 0 (0) 0 (0) 2 (100)
Bacterial vaginosis requiring treatment:
No 19 (9.7) 130 (66.3) 47 (24.0) 0.16
Yes 0 (0) 6 (50.0) 6 (50.0)
Candidiasis requiring treatmente:
No 17 (9.5) 116 (64.8) 46 (25.7) 0.10
Yes 0 (0) 10 (100) 0 (0)
Abbreviations: KRST Kenya, Rwanda, South Africa, and Tanzania.
*Fisher’s exact test, Trend = Chi-squared test for trend.
a4/208 values missing.
bNo association (p = 0.95) was found when the data were analyzed with a binary outcome (i.e. clusters KRST-I and KRST-II combined vs. cluster KRST-pIII-V).
cBacterial STIs includes syphilis (by serology), chlamydia and gonorrhea (by PCR), and trichomoniasis (by InPouch culture test).
dStronger evidence of association was observed when data were analyzed with a binary outcome (i.e. clusters KRST-I and II combined vs. cluster KRST-pIII-V)
(p = 0.06) and when pregnant women and Tanzanian women (phase in the menstrual cycle at the time of sampling not known) were excluded (p = 0.04).
e19/208 values missing.
†Women who had mild/moderate cervical mucus (OR = 0.27; 95% CI 0.09, 0.81) and women who had abundant cervical mucus (OR = 0.09; 95% CI 0.01, 0.68) were
more likely to belong to cluster KRST-II vs. KRST-I compared to women with no cervical mucus. Women who had mild cervical mucus compared to no cervical
mucus were less likely to belong to cluster KRST-pIII-V vs. KRST-I (OR = 0.28; 95% CI 0.08, 0.93), while there was no statistically significant difference between
having abundant cervical mucus and no cervical mucus.
Figure 3 BV status distribution by Nugent score (a) and Amsel criteria (b) in the three VMB clusters. In Figure 3a, women were classified
as BV-negative (BV-), BV intermediate (BVint), or BV-positive (BV+) based on Nugent score of 0–3, 4–6 and 7–10, respectively. In Figure 3b, women
were classified as BV-positive if any three of the four Amsel criteria (i.e. clue cells > 20%, positive whiff test, vaginal pH > 4.5, and/or presence of
unusual vaginal discharge) was positive. The error bars correspond to the 95% confidence interval of the proportions.
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Table 3 Immunological correlates of VMB clusters
Correlates KRST-I (n = 19) KRST-II (n = 136) KRST-pIII-V (n = 53) p value*a
(in log10) Mean (95% CI) OR/aOR (95% CI) Mean (95% CI) OR (95% CI) aOR (95% CI) Mean (95% CI) OR (95% CI) aOR (95% CI)
IL-1α 1.08 (0.86, 1.3) Ref 1.22 (1.14, 1.31) 1.61 (0.69, 3.77) 1.58 (0.58, 4.33) 1.64 (1.48, 1.81) 7.4 (2.63, 20.82) 11.5† (3.29, 40.22) <0.0001
IL-1β 0.65 (0.33, 0.97) Ref 0.83 (0.71, 0.95) 1.4 (0.72, 2.74) - 1.34 (1.11, 1.57) 3.33 (1.58, 7.03) - <0.0001
IL-1rab 4.65 (4.36, 4.94) Ref 4.83 (4.74, 4.91) 1.9 (0.76, 4.76) - 4.87 (4.74, 5) 2.28 (0.79, 6.6) - 0.28
IL-6 0.64 (0.33, 0.95) Ref 0.9 (0.79, 1) 1.68 (0.85, 3.3) - 0.9 (0.68, 1.11) 1.68 (0.8, 3.54) - 0.31
IL-8 2.06 (1.83, 2.28) Ref 2.19 (2.09, 2.28) 1.41 (0.62, 3.2) - 2.25 (2.04, 2.45) 1.65 (0.68, 3.97) - 0.54
IL-12c 0.07 (−0.18, 0.32) Ref 0.13 (0.05, 0.21) 1.31 (0.45, 3.81) - 0.24 (0.12, 0.35) 2.11 (0.66, 6.7) - 0.28
IP-10 2.54 (2.36, 2.73) Ref 2.62 (2.51, 2.73) 1.22 (0.57, 2.6) 0.98 (0.39, 2.43) 2.15 (1.93, 2.38) 0.47 (0.21, 1.06) 0.16† (0.05, 0.47) 0.0002
GM-CSF 0.26 (0.05, 0.47) Ref 0.32 (0.25, 0.39) 1.38 (0.47, 4.03) - 0.13 (−0.01, 0.27) 0.58 (0.19, 1.78) - 0.0351
G-CSF 1.84 (1.57, 2.11) Ref 1.91 (1.79, 2.02) 1.16 (0.57, 2.38) 0.71 (0.26, 1.92) 2.08 (1.93, 2.23) 1.83 (0.81, 4.15) 3.6†† (1.02, 12.73) 0.18
MIP-1βd 0.69 (0.23, 1.15) Ref 0.94 (0.83, 1.05) 1.57 (0.84, 2.94) 1.73 (0.79, 3.82) 0.7 (0.48, 0.93) 1.02 (0.52, 1.98) 0.61 (0.25, 1.52) 0.085
Abbreviations: CI confidence interval, KRST Kenya, Rwanda, South Africa, Tanzania, OR odds ratio, aOR adjusted odds ratio. For cytokine and growth factor abbreviations, we refer to the text.
*One way analysis of variance test in a bivariable analysis.
aSix variables qualified for inclusion in the multivariable model but only four (IL-1α, IP-10, G-CSF, and MIP-1β) variables remained in the final model after the model selection process. Although, IL-1β was highly
significant in the bivariable analysis, it was eliminated during the model selection because it was highly correlated with IL-1α (Pearson’s correlation coefficient = 0.65).
b19/208 values missing.
cStronger evidence of association was observed when pregnant women and Tanzanian women (stage of menstrual cycle at time of sampling not known) were excluded (p = 0.09).
dWeaker evidence of association was observed when pregnant women and Tanzanian women (stage of menstrual cycle at time of sampling not known) were excluded (p = 0.27).
†Adjusted P-value < 0.001.
††Adjusted P-value = 0.01.
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Europe and Asia but were less common than clusters
dominated by L. crispatus or L. iners [8,10,28,29]. We
found that Nugent scoring correlated well with molecular
VMB clustering but the Amsel criteria did not, as has
been found by others [reviewed in 6]. This may have
clinical relevance since the Amsel criteria are often used
in clinic settings to diagnose BV.
Women in the pooled dysbiotic cluster KRST-pIII-V
had higher concentrations of several pro-inflammatory
factors than women in clusters KRST-I and II. In the
past, BV has often been described as a non-inflammatory
syndrome, but more recent data consistently show that
vaginal dysbiosis is associated with subclinical cervico-
vaginal immune activation [19,30]. The differences in
inflammatory markers could also partially be explained by
hormonal differences between the VMB clusters such as
stage of the menstrual cycle, use of hormonal contracep-
tion and pregnancy. A recent systematic review showed
that hormonal contraceptive use and pregnancy are nega-
tively associated with vaginal dysbiosis [31], and it has
been suggested that pregnancy is associated with a pro-
inflammatory state [32]. However, in this study, hormonal
contraceptive use and pregnancy were not associated with
VMB clustering and a sensitivity analysis excluding the
pregnant women and women from Tanzania (for whom
we did not know the stage of the menstrual cycle at the
time of sampling) did not change our results substantively
(see footnotes Table 3). Inflammation related to vaginal
dysbiosis is of concern because vaginal dysbiosis is very
common (25.5% in this study) [33] and inflammation in
the genital tract results in the attraction of CD4+ target
cells for HIV [20] as well as shedding of HIV in HIV-
positive women [34]. There was no evidence for an associ-
ation between VMB clustering and HIV prevalence in this
study (likely due to the small number of HIV infections)
but we recently showed a strong association (using the
same phylogenic microarray as in this study) in female sex
workers in Kigali, Rwanda [3].
There was some evidence that a lower proportion of
women in cluster KRST-I tested positive for STIs
(ptrend = 0.07) and UTIs (p = 0.06) than in the other clus-
ters, but the number of cases was small. These findings
are, however, consistent with the findings of the above-
mentioned study in female sex workers in Kigali that
reported negative associations between a L. crispatus-
dominated VMB and various STIs [3]. Other studies have
also shown that lactobacilli-dominated VMB [reviewed in
6] or a Nugent score 0–3 [4,5,35] are negatively associated
with both viral and bacterial STIs. The relationship
between the VMB and UTIs has not been adequately
studied, but recent studies have shown that the urine
microbiome in women resembles their VMB [36]. In con-
trast, a higher proportion of women in clusters KRST-I
and II had vaginal candidiasis than women in the other
clusters (ptrend = 0.09), and this is consistent with findings
of several other studies (reviewed in [6]).
We identified few additional correlates of VMB compos-
ition, perhaps due to limited statistical power. Women
who had delivered a baby more recently were more likely
to belong to clusters KRST-I and KRST-II (p = 0.01),
whereas women who reported unusual vaginal dis-
charge were more likely to belong to clusters KRST-III/
IV/V (p = 0.05). The former could be explained by sex
hormone levels but this seems unlikely since the median
time period since the last delivery was at least 33 months in
all three groups. Confounding by age or sexual behavior
might be more likely. There was some evidence that
women in the KRST-I cluster were older, had fewer sexual
partners in the last three months, but more unprotected
sex with a steady partner, than women in the other clusters.
Our study used samples and data from two studies.
While we used the same VMB assessment methods in
both studies, there were some differences in other assess-
ments such as the way questions were asked, the test kits
that were used for on-site diagnostic testing, and the plat-
forms that were used in Antwerp and London for cytokine
testing [37]. Other limitations include the cross-sectional
nature of the study, the small sample sizes in some of the
comparison groups (particularly the number of HIV and
bacterial STI cases), and the imprecise timing of sexual
behaviors (in the Vaginal Biomarkers Study), STI and UTI
diagnoses (in the Vaginal Biomarkers Study) and stage of
the menstrual cycle (in the Tanzania study) relative to
microarray sampling.
Conclusions
Vaginal dysbiosis in African women was significantly
associated with vaginal inflammation. The associations
with increased prevalence of STIs (including HIV) and
UTIs, and decreased prevalence of vaginal candidiasis,
should be confirmed in larger studies.
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